NASDAQ:XOMA XOMA (XOMA) Stock Forecast, Price & News $17.01 +0.01 (+0.06%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$16.53▼$17.3150-Day Range$17.00▼$22.2352-Week Range$15.68▼$32.08Volume94,261 shsAverage Volume32,677 shsMarket Capitalization$194.95 millionP/E RatioN/ADividend YieldN/APrice Target$69.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability XOMA MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside305.6% Upside$69.00 Price TargetShort InterestBearish4.98% of Shares Sold ShortDividend StrengthN/ASustainability-0.22Upright™ Environmental ScoreNews Sentiment0.65Based on 4 Articles This WeekInsider TradingAcquiring Shares$131,439 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.44) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector1161st out of 1,980 stocksPharmaceutical Preparations Industry577th out of 978 stocks 3.5 Analyst's Opinion Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $69.00, XOMA has a forecasted upside of 305.6% from its current price of $17.01.Amount of Analyst CoverageXOMA has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.98% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 19.9, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently increased by 1.86%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for XOMA is -0.22. Previous Next 2.6 News and Social Media Coverage News SentimentXOMA has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for XOMA this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for XOMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have bought more of their company's stock than they have sold. Specifically, they have bought $131,439.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions54.89% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.44) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About XOMA (NASDAQ:XOMA) StockXOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.Read More Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMA Stock News HeadlinesMay 28, 2023 | americanbankingnews.comInsider Buying: XOMA Co. (NASDAQ:XOMA) CIO Purchases $16,150.00 in StockMay 28, 2023 | americanbankingnews.comXOMA Co. (NASDAQ:XOMA) CEO Owen Hughes Purchases 968 SharesJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 24, 2023 | msn.comXOMA's Return On Capital Employed InsightsMay 24, 2023 | americanbankingnews.comBradley Sitko Acquires 1,000 Shares of XOMA Co. (NASDAQ:XOMA) StockMay 23, 2023 | seekingalpha.comXOMAP XOMA Corporation 8.625% CUM PERP PFD SER AMay 19, 2023 | americanbankingnews.comXOMA (NASDAQ:XOMA) Receives New Coverage from Analysts at StockNews.comMay 18, 2023 | americanbankingnews.comInsider Buying: XOMA Co. (NASDAQ:XOMA) CIO Buys 1,500 Shares of StockJune 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 17, 2023 | americanbankingnews.comXOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Buys 2,000 Shares of StockMay 16, 2023 | finance.yahoo.comShareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years agoMay 11, 2023 | finance.yahoo.comAcorda Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comXOMA: Q1 Earnings InsightsMay 10, 2023 | msn.comXOMA GAAP EPS of -$0.98, revenue of $0.44MMay 9, 2023 | finance.yahoo.comXOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyApril 26, 2023 | finance.yahoo.comXOMA to Present at H.C. Wainwright BioConnect Investor ConferenceMarch 30, 2023 | finance.yahoo.comXOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioMarch 10, 2023 | finance.yahoo.comXOMA Full Year 2022 Earnings: Revenues Beat Expectations, EPS In LineMarch 9, 2023 | finance.yahoo.comXOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization StrategyMarch 6, 2023 | finance.yahoo.comXOMA Corporation's (NASDAQ:XOMA) largest shareholders are individual investors with 37% ownership, hedge funds own 32%March 6, 2023 | marketwatch.com2023-2029 Acute Coronary Syndrome Therapeutics Market Size and Growth Analysis | Research Report by Absolute ReportsFebruary 28, 2023 | prnewswire.comHONOR Magic5 Pro занял верхнюю строчку рейтинга DXOMARK благодаря камере и дисплеюFebruary 28, 2023 | prnewswire.comHONOR Magic5 Pro je na čele rebríčka fotoaparátov a displejov DXOMARKFebruary 28, 2023 | finance.yahoo.comXOMA to Present at 43rd Annual Cowen Health Care ConferenceFebruary 22, 2023 | prnewswire.comLe HONOR Magic5 Lite est lancé sur les marchés européens et décroche la première place du classement mondial des batteries de DXOMARKFebruary 14, 2023 | finance.yahoo.comXOMA Corporation (XOMA) Stock Historical Prices & Data - Yahoo FinanceFebruary 8, 2023 | marketwatch.comBotulism Illness Market to Grow Significantly by Leading Players 2023 to 2028See More Headlines XOMA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XOMA Company Calendar Last Earnings3/09/2023Today6/01/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:XOMA CUSIP98419J10 CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees12Year Founded1981Price Target and Rating Average Stock Price Forecast$69.00 High Stock Price Forecast$69.00 Low Stock Price Forecast$69.00 Forecasted Upside/Downside+305.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,100,000.00 Net Margins-774.65% Pretax Margin-734.35% Return on Equity-20.65% Return on Assets-18.11% Debt Debt-to-Equity RatioN/A Current Ratio4.47 Quick Ratio4.47 Sales & Book Value Annual Sales$6.03 million Price / Sales32.31 Cash FlowN/A Price / Cash FlowN/A Book Value$9.99 per share Price / Book1.70Miscellaneous Outstanding Shares11,460,000Free Float10,865,000Market Cap$194.82 million OptionableNot Optionable Beta0.84 Social Links Key ExecutivesOwen Patrick HughesChairman & Chief Executive OfficerThomas BurnsChief Financial Officer & Senior VP-FinanceBradley J. SitkoChief Investment OfficerJuliane SnowdenInvestor Relations ContactKey CompetitorsVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKSpectrum PharmaceuticalsNASDAQ:SPPIRigel PharmaceuticalsNASDAQ:RIGLFortress BiotechNASDAQ:FBIOView All CompetitorsInsiders & InstitutionsBradley SitkoBought 850 shares on 5/23/2023Total: $16,150.00 ($19.00/share)Owen HughesBought 968 shares on 5/23/2023Total: $22,709.28 ($23.46/share)Bradley SitkoBought 1,000 shares on 5/19/2023Total: $19,500.00 ($19.50/share)BVF Inc. ILBought 22,249 shares on 5/16/2023Ownership: 31.705%Geode Capital Management LLCBought 1,748 shares on 5/16/2023Ownership: 0.713%View All Insider TransactionsView All Institutional Transactions XOMA Stock - Frequently Asked Questions Should I buy or sell XOMA stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA shares. View XOMA analyst ratings or view top-rated stocks. What is XOMA's stock price forecast for 2023? 1 equities research analysts have issued twelve-month price objectives for XOMA's stock. Their XOMA share price forecasts range from $69.00 to $69.00. On average, they predict the company's stock price to reach $69.00 in the next year. This suggests a possible upside of 305.9% from the stock's current price. View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts. How have XOMA shares performed in 2023? XOMA's stock was trading at $18.40 at the start of the year. Since then, XOMA stock has decreased by 7.6% and is now trading at $17.00. View the best growth stocks for 2023 here. When is XOMA's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our XOMA earnings forecast. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings results on Thursday, March, 9th. The biotechnology company reported ($0.64) EPS for the quarter. The biotechnology company had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.62 million. XOMA had a negative trailing twelve-month return on equity of 20.65% and a negative net margin of 774.65%. What is John Varian's approval rating as XOMA's CEO? 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO). What is XOMA's stock symbol? XOMA trades on the NASDAQ under the ticker symbol "XOMA." Who are XOMA's major shareholders? XOMA's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (31.71%), FMR LLC (10.77%), Stonepine Capital Management LLC (2.78%), Acuitas Investments LLC (0.76%), Geode Capital Management LLC (0.71%) and Susquehanna International Group LLP (0.44%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes, Thomas M Burns and Value Fund L P Biotechnology. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is XOMA's stock price today? One share of XOMA stock can currently be purchased for approximately $17.00. How much money does XOMA make? XOMA (NASDAQ:XOMA) has a market capitalization of $194.82 million and generates $6.03 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. How can I contact XOMA? XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571. This page (NASDAQ:XOMA) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.